news
Early promise for novel breast cancer immunotherapy
With potential “groundbreaking” results, the immunotherapy could alter the need for breast cancer patients to undertake chemotherapy, trial investigators suggest.
List view / Grid view
trastuzumab
news
Acquisition deal to back European biosimilars market
Following the acquisition from Viatris, Biocon Biologics and its partners state that they will commercialise biosimilar products in 31 European countries.
news
EMA’s human medicines committee (CHMP) May 2022 meeting highlights
The latest meeting saw EMA’s human medicines committee (CHMP) recommend the approval of nine new medicines, refuse two biosimilar medications and recommend extensions of therapeutic indication for six medicines.
news
NICE does not recommend tucatinib in new draft guidance
The UK regulator concluded that breast cancer patients taking tucatinib live longer, but it is unclear how long for and whether it is cost effective.
news
Ultrasound delivers antibody therapy for HER2-positive brain metastasis
MR-guided focused ultrasound safely delivered antibody therapy to breast cancer that has metastasised to the brain in Phase I study.
news
UK grants marketing authorisation to “landmark” breast cancer therapy
Seagen's Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
news
Biologics patent expiry to positively impact US pharma, says report
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
news
WHO announces first biosimilar medicine pre-qualification
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
news
FDA antibody biosimilar product approvals increase in 2019
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
news
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer...
news
Trastuzumab taken with carvedilol leads to less heart damage
A team of Iranian researchers have determined that trastuzumab taken with a heart drug leads to less heart damage in breast cancer patients...
news
Anti-HER2 drug benefits patients with stomach and bowel cancer
The antibody ZW25 can bind two distinct regions of the HER2 receptor to block the growth of cancer cells and has shown signs of anti-tumour activity...
news
HER2+ breast cancers may benefit from short-course trastuzumab
A study trialling a short course of trastuzumab in HER2 positive breast cancer patients showed that it is as effective and cheaper than a longer course...
news
Cardiac monitoring for high-risk breast cancer patients ‘should be prioritised’
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
